SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549

                                    FORM 10-Q

(Mark One)


[x] Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange
    Act of 1934

For the quarterly period ended September 30, 2002

[ ] Transition report pursuant to Section 13 or 15(d) of the Securities
    Exchange Act of 1934

For the transition period from ___________________ to ___________________


Commission file number: 0-16594

                        MEDICAL TECHNOLOGY SYSTEMS, INC.
--------------------------------------------------------------------------------
             (Exact Name of Registrant as Specified in Its Charter)


           DELAWARE                                           59-2740462
---------------------------------                       ----------------------
(State or other jurisdiction of                            (I.R.S.) Employer
 Incorporation or Organization)                           Identification No.)


              12920 Automobile Boulevard, Clearwater, Florida 33762
--------------------------------------------------------------------------------
                    (Address of Principal Executive Offices)


                                  727-576-6311
--------------------------------------------------------------------------------
              (Registrant's Telephone Number, Including Area Code)


--------------------------------------------------------------------------------
              (Former Name, Former Address and Former Fiscal Year,
                          if changed since last report)


     Indicate by check mark  whether the  registrant:  (1) has filed all reports
required to be filed by Section 13 or 15(d) of the  Securities  Exchange  Act of
1934  during  the  preceding  12 months  (or for such  shorter  period  that the
registrant  was required to file such  reports) and (2) has been subject to such
filing requirements for the past 90 days.    Yes   X    No
                                                 -----     -----


     Indicate by check mark whether the  Registrant  has filed all documents and
reports  required  to be  filed by  Section  12,  13 or 15(d) of the  Securities
Exchange Act of 1934 subsequent to the  distribution of securities  under a plan
confirmed by a court.   Yes   X    No
                            -----     -----


                                      10Q-1

<PAGE>
                                       i.


                MEDICAL TECHNOLOGY SYSTEMS, INC. AND SUBSIDIARIES

                                      Index

                                                                            Page

Part I -  Financial Information


Item 1.   Financial Statements

          Condensed Consolidated Balance Sheets -
             September 30, 2002 and March 31, 2002......................       1


          Condensed Consolidated Statements of Earnings -
             Three and Six Months Ended September 30, 2002 and 2001.....       2


          Condensed Consolidated Statements of Changes in Stockholders'
             Equity - Six Months Ended September 30, 2002...............       3


          Condensed Consolidated Statements of Cash Flows -
             Six Months Ended September 30, 2002 and 2001...............       4


          Notes to Condensed Consolidated Financial Statements..........  5 - 12


Item 2.   Management's Discussion and Analysis of Financial
             Condition and Results of Operations........................ 13 - 16


Item 3.   Quantitative and Qualitative Disclosures About Market Risk....      17


Item 4.   Controls and Procedures.......................................      17


Part II - Other Information


Item 4.   Submission of Matters to a Vote of Security Holders...........      18


Item 6.   Exhibits and Reports on Form 8-K..............................      18


          Signatures....................................................     18


Certifications.......................................................... 19 - 20




<PAGE>
                                       1



Item 1.  Financial Statements


                         PART 1 - FINANCIAL INFORMATION

                MEDICAL TECHNOLOGY SYSTEMS, INC. AND SUBSIDIARIES
                      CONDENSED CONSOLIDATED BALANCE SHEETS
                                 (In Thousands)


                                     ASSETS

<TABLE>
<CAPTION>
                                                                         September 30,               March 31,
                                                                             2002                      2002
                                                                       ----------------          -----------------
                                                                         (Unaudited)
<S>                                                                    <C>                        <C>
Current Assets:
     Cash                                                              $           220            $           410
     Accounts Receivable, Net                                                    3,482                      3,456
     Inventories                                                                 2,698                      2,212
     Prepaids and Other                                                            279                        199
     Deferred Tax Benefits                                                       1,232                      1,232
                                                                       ----------------          -----------------
     Total Current Assets                                                        7,911                      7,509

Property and Equipment, Net                                                      2,725                      2,425
Other Assets, Net                                                                2,994                      2,477
Deferred Tax Benefits                                                            2,665                      3,104
                                                                       ----------------          -----------------

Total Assets                                                           $        16,295            $        15,515
                                                                       ================          =================


                 LIABILITIES AND STOCKHOLDERS' EQUITY


Current Liabilities:
     Current Maturities of Long-Term Debt                              $         1,169           $            968
     Accounts Payable and Accrued Liabilities                                    3,398                      3,267
                                                                       ----------------          -----------------
     Total Current Liabilities                                                   4,567                      4,235

Long-Term Debt, Less Current Maturities                                          7,392                     10,812
                                                                       ----------------          -----------------
Total Liabilities                                                               11,959                     15,047
                                                                       ----------------          -----------------
Stockholders' Equity:
     Common Stock                                                                   44                         43
     Preferred Stock                                                                 1                          0
     Capital In Excess of Par Value                                             11,947                      8,806
     Accumulated Deficit                                                        (7,328)                    (8,053)
     Treasury Stock                                                               (328)                      (328)
                                                                       ----------------          -----------------
     Total Stockholders' Equity                                                  4,336                        468
                                                                       ----------------          -----------------
     Total Liabilities and Stockholders' Equity                        $        16,295           $         15,515
                                                                       ================          =================
</TABLE>

The accompanying notes are an integral part of these financial statements.


<PAGE>
                                       2



                MEDICAL TECHNOLOGY SYSTEMS, INC. AND SUBSIDIARIES
                  CONDENSED CONSOLIDATED STATEMENTS OF EARNINGS
                (In Thousands; Except Earnings Per Share Amounts)

                                   (Unaudited)


<TABLE>
<CAPTION>
                                                                Three Months Ended                  Six Months Ended
                                                                  September 30,                       September 30,
                                                         -------------------------------     -------------------------------
                                                              2002              2001              2002              2001
                                                         --------------    -------------     --------------    -------------
<S>                                                      <C>               <C>               <C>               <C>
Revenue:
      Net Sales                                          $       6,719     $      5,991      $      13,626     $     11,867

Costs and Expenses:
      Cost of Sales                                              4,085            3,495              8,412            6,975
      Selling, General and Administrative                        1,541            1,346              3,012            2,656
      Depreciation and Amortization                                251              233                436              457
                                                         --------------    -------------     --------------    -------------
Total Costs and Expenses                                         5,877            5,074             11,860           10,088
                                                         --------------    -------------     --------------    -------------

Operating Profit                                                   842              917              1,766            1,779

Other Expenses
      Interest Expense                                             228              241                449              481
      Amortization of:
          Financing Costs                                           85                0                 89                0
          Original Issue Discount                                   62                0                 65                0
                                                         --------------    -------------     --------------    -------------
Total Other Expenses                                               375              241                603              481

Income Before Income Taxes                                         467              676              1,163            1,298

Income Tax Expense                                                 177              237                438              476
                                                         --------------    -------------     --------------    -------------

Net Income                                                         290              439                725              822

Non-Cash Constructive Dividend Related to
      Beneficial Conversion Feature of Convertible
          Preferred Stock                                            0                0                347                0

Convertible Preferred Stock Dividends                               55                0                 58                0
                                                         --------------    -------------     --------------    -------------

Net Income Available to Common Stockholders              $         235     $        439      $         320     $        822
                                                         ==============    =============     ==============    =============

Net Income Per Basic Common Share                        $        0.05     $       0.10      $        0.07     $       0.19
                                                         ==============    =============     ==============    =============

Net Income Per Diluted Common Share                      $        0.04     $       0.10      $        0.06     $       0.19
                                                         ==============    =============     ==============    =============

</TABLE>


The accompanying notes are an integral part of these financial statements.



<PAGE>
                                       3


                MEDICAL TECHNOLOGY SYSTEMS, INC. AND SUBSIDIARIES
      CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY
                       SIX MONTHS ENDED SEPTEMBER 30, 2002
                                 (In Thousands)
                                   (Unaudited)


<TABLE>
<CAPTION>
                                     Common Stock       Preferred Stock
                                    $.01 Par Value      $.001 Par Value       Capital                                     Total
                                 --------------------  -----------------     In Excess     Accumulated    Treasury    Stockholder's
                                   Shares    Amount     Shares   Amount    of Par Value      Deficit        Stock        Equity
                                 ---------- --------   -------- --------  --------------  -------------  ----------  ---------------
<S>                              <C>        <C>        <C>      <C>       <C>             <C>            <C>         <C>
Balance, March 31, 2002          4,331,161   $   43         0    $   0      $    8,806      $  (8,053)     $ (328)      $     468

Stock Options and Warrants
 Exercised                          40,362        1                                  4                                          5

Warrants Issued                                                                  1,564                                      1,564

Preferred Stock Issued                                  2,000        1           1,999                                      2,000

Costs Related to Equity Issued                                                    (368)                                      (368)

Convertible Preferred Stock
 Dividend                                                                          (58)                                       (58)

Non-Cash Constructive Dividend
 Related to Beneficial Conversion
  Feature of Convertible
   Preferred Stock                                                                (347)                                      (347)

Amortization of Non-Cash
 Constructive Dividend related to
  Beneficial Conversion Feature
   of Convertible Preferred Stock                                                  347                                        347

Net Income for Six Months Ended
 September 30, 2002                                                                               725                         725
                                 ---------- --------  --------  --------  --------------  -------------  ----------  ---------------

Balance September 30, 2002       4,371,523   $   44     2,000    $    1     $   11,947      $  (7,328)     $ (328)      $   4,336
                                 ========== ========  ========  ========  ==============  =============  ==========  ===============

</TABLE>



<PAGE>
                                       4


                MEDICAL TECHNOLOGY SYSTEMS, INC. AND SUBSIDIARIES
                 CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
                                 (In Thousands)
                                   (Unaudited)

<TABLE>
<CAPTION>
                                                                                               Six Months Ended
                                                                                                 September 30,
                                                                                    -------------------------------------
                                                                                         2002                    2001
                                                                                    -------------           -------------
<S>                                                                                 <C>                     <C>
Operating Activities
    Net Income                                                                      $        725            $        862
                                                                                    -------------           -------------
    Adjustments to Reconcile Net Income to Net Cash
       Provided by Operating Activities:
       Obsolete Inventory Written Off                                                         29                       0
       Deferred Compensation                                                                   0                       4
       Amortization of Original Issue Discount                                                65                       0
       Amortization of Deferred Financing Costs                                               89                       0
       Depreciation and Amortization                                                         436                     457
       Income Tax Expense                                                                    438                     476
       (Increase) Decrease in:
           Accounts Receivable                                                               (26)                   (316)
           Inventories                                                                        39                     166
           Prepaids and Other                                                                (80)                    (60)
       Increase in:
           Accounts Payable and Other Accrued Liabilities                                    131                     125
                                                                                    -------------           -------------
    Total Adjustments                                                                      1,121                     852
                                                                                    -------------           -------------
    Net Cash Provided by Operating Activities                                              1,846                   1,714
                                                                                    -------------           -------------

Investing Activities
    Expended for Property and Equipment                                                     (503)                   (662)
    Expended for Product Development                                                        (259)                   (296)
    Expended for Patents and Other Assets                                                    (44)                    (15)
                                                                                    -------------           -------------
    Net Cash Used by Investing Activities                                                   (806)                   (973)
                                                                                    -------------           -------------

Financing Activities
    Payments on Notes Payable and Long-Term Debt                                         (11,781)                   (574)
    Net Advances on Revolving Line of Credit                                               3,039                       0
    Borrowing on Term Loans and Subordinated Notes                                         6,700                       0
    Issuance of Convertible Preferred Stock                                                2,000                       0
    Expended for Financing Costs                                                          (1,130)                      0
    Dividends on Convertible Preferred Stock                                                 (58)                      0
    Advances (To) Affiliates - Discontinued Operations                                         0                    (169)
                                                                                    -------------           -------------
    Net Cash Used by Financing Activities                                                 (1,230)                   (743)
                                                                                    -------------           -------------

Net Decrease in Cash                                                                        (190)                     (2)
Cash at Beginning of Period                                                                  410                      92
                                                                                    -------------           -------------
Cash at End of Period                                                               $        220            $         90
                                                                                    =============           =============

</TABLE>

See Note L for supplemental disclosures of other cash flow information.

The accompanying notes are an integral part of these financial statements.


<PAGE>
                                       5


                MEDICAL TECHNOLOGY SYSTEMS, INC. AND SUBSIDIARIES
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                   FOR THE SIX MONTHS ENDED SEPTEMBER 30, 2002


NOTE A - BASIS OF PRESENTATION

     The accompanying unaudited condensed consolidated financial statements have
been prepared in accordance with accounting principles generally accepted in the
United States of America (US GAAP) for interim  financial  information  and with
the  instructions  to Form 10-Q and Article 10 of Regulation  S-X.  Accordingly,
they do not include all of the information and notes required by the US GAAP for
complete  financial  statements.  In the opinion of management,  all adjustments
(consisting  of  normal  recurring  accruals)  considered  necessary  for a fair
presentation have been included.  Operating results for the three- and six-month
periods ended September 30, 2002 are not  necessarily  indicative of the results
that may be expected for the year ended March 31, 2003. The unaudited  condensed
consolidated  financial  statements  should  be read  in  conjunction  with  the
consolidated  financial  statements and notes thereto  included in the Company's
annual report on Form 10-K for the year ended March 31, 2002.

     The  unaudited  condensed  consolidated  financial  statements  include the
accounts of the Company and its subsidiary,  MTS Packaging  Systems,  Inc. ("MTS
Packaging").  All other  subsidiaries  of the  Company  did not have  operations
during the three and six months ended September 30, 2002 and 2001.


NOTE B - INVENTORIES

     The components of inventory consist of the following:


                                             September 30,          March 31,
                                                 2002                 2002
                                         -----------------     -----------------
                                                     (In Thousands)

Raw Materials                              $       1,094         $         964
Finished Goods and Work in Progress                1,673                 1,288
Less:  Inventory Valuation Allowance                 (69)                  (40)
                                         -----------------     -----------------
                                           $       2,698         $       2,212
                                         =================     =================


     Inventories  are  stated  at the  lower of cost  (first-in,  first-out)  or
market.


NOTE C - EARNINGS PER SHARE

     Net Income per common share is computed by dividing net income available to
common  shareholders by the basic and diluted  weighted average number of shares
of common stock  outstanding.  For diluted weighted average shares  outstanding,
the  Company  used the  treasury  stock  method to  calculate  the Common  Stock
equivalents  that the stock options and warrants would  represent.  In addition,
the  convertible  preferred  stock has been treated as if it had been  converted
into common stock on the date of issuance.

     The CEO of the Company  may elect to receive  shares of  restricted  common
stock  in  lieu  of  cash  compensation  according  to the  terms  of his  Stock
Appreciation Rights Agreement with the Company. The terms of the Company's prior
loan agreement  restricted  his ability to make the election to receive  shares;
however,  the terms of the Company's current loan agreements do not contain such
a restriction.  As a result,  the Company has included the number of shares that
he could elect to receive in lieu of cash,  in its  calculation  of earnings per
share.


<PAGE>
                                       6


     The  following  table  sets forth the  computation  of income per basic and
diluted common share:

<TABLE>
<CAPTION>
                                                              Three Months Ended                 Six Months Ended
                                                        ------------------------------   -------------------------------
                                                         September 30,   September 30,    September 30,    September 30,
                                                             2002             2001            2002             2001
                                                        --------------   -------------   --------------   --------------
<S>                                                     <C>              <C>             <C>              <C>
Numerator:

 Net Income                                              $       290      $      439      $       725      $       822

   Minus:
     Constructive Dividend Related to Beneficial
       Conversion Feature of the Convertible
          Preferred Stock                                          0               0              347                0

      Convertible Preferred Stock Dividend                        55               0               58                0
                                                       ---------------  --------------  ---------------  ---------------

Net Income Available to Common Stockholders                      235             439              320              822
                                                       ---------------  --------------  ---------------  ---------------

Denominator:

   Weighted Average Shares Outstanding - Basic                 4,363           4,308            4,347            4,271

   Add: Effect of Dilutive Warrants and Options                  945              92              616              138

   Effect of Conversion of Convertible Preferred
     Stock into Common Stock                                     847               0              447                0

   Effect of Shares Available for Issuance under SAR
     Agreement                                                   239               0              239                0
                                                       ---------------  --------------  ---------------  ---------------

   Weighted Average Shares Outstanding - Diluted               6,394           4,400            5,649            4,409
                                                       ===============  ==============  ===============  ===============

Net Income Per Basic Common Share                       $       0.05      $     0.10      $      0.07      $      0.19
                                                       ===============  ==============  ===============  ===============

Net Income Per Diluted Common Share                     $       0.04      $     0.10      $      0.06      $      0.19
                                                       ===============  ==============  ===============  ===============

</TABLE>


     Certain  provisions  of the  warrants  and  the  terms  of the  convertible
preferred  stock  issued in June 2002 may result in the  issuance of  additional
shares at some future date if certain events occur.  Since these events have not
yet occurred,  and therefore  the number of additional  shares is not known,  no
additional  shares have been included in the earnings per share calculation (see
Note H).


<PAGE>
                                       7


NOTE D - REVENUE RECOGNITION

     The  Company  recognizes  revenue  when  products  are  shipped  and  title
transfers.  Revenue  includes  certain amounts invoiced to customers for freight
and handling charges.

     The Company  includes the actual cost of freight and  handling  incurred in
cost of sales.  The actual cost of freight and handling for the six months ended
September 30, 2002 and 2001 was $803,000 and $663,000 respectively.


NOTE E - RESEARCH AND DEVELOPMENT AND PRODUCT DEVELOPMENT

     The Company expenses  product  research and development  costs as incurred.
The Company  incurred  approximately  $57,000 and $47,000  during the six months
ended  September  30, 2002 and 2001  respectively  for research and  development
costs.

     All costs incurred subsequent to the completion of research and development
activities  associated with the product's  hardware  components and the software
components  achievement of technological  feasibility are capitalized  until the
product is available  for general  release to customers.  The Company  initially
classifies the construction costs of the first units produced for commercial use
as product development costs prior to transferring these costs to inventory. The
Company capitalized  approximately  $259,000 and $296,000 of product development
costs during the six months ended September 30, 2002 and 2001 respectively.

     Product  development costs are generally amortized on a straight-line basis
over a five (5) year period. Amortization expense related to product development
costs was $102,000 and $39,000 for the six months ended  September  30, 2002 and
2001 respectively.

     At March 31, 2002 and September 30, 2002, the Company's capitalized product
development  costs  included  its  new  OnDemand   product,   which  represented
$1,314,000  and  $1,078,500   respectively  of  the  total  capitalized  product
development costs (see Note L).  Manufacturing  costs of approximately  $441,000
were included in the OnDemand capitalized product development costs at March 31,
2002. All manufacturing costs of the OnDemand product were included in inventory
at September  30, 2002.  The Company  expects that an  additional  approximately
$250,000  will be  expended  during the  current  fiscal  year to  complete  the
development of the OnDemand product.

     The first  OnDemand  machine  was sold in June 2002.  The  second  OnDemand
machine has been installed at a customer's  location.  Once certain  performance
specification are met and the customer formally accepts the machine, the Company
will record the revenue associated with this installation.



<PAGE>
                                       8



NOTE F - LONG-TERM DEBT

     Long-term debt consists of the following:

<TABLE>
<CAPTION>
                                                                                    September 30,       March 31,
                                                                                         2002             2002
                                                                                    -------------    --------------
                                                                                             (In Thousands)
<S>                                                                                 <C>              <C>
  Bank Term Loan payable in installments of interest at 7.5% and principal
    monthly for ten years ending September 1, 2006, with a lump sum payment of
    approximately $7.1 million on that date secured by all tangible and
    intangible assets of the Company.                                                $       0       $    11,449

  Revolving  Line of Credit  due June 26,  2005 plus  interest  payable  at 1%
    above the prime rate (5.75% at September 30, 2002).                                  3,040                 0

  Bank Term Loan payable in monthly  installments  of $83,333 plus interest at
    2.25% above the prime rate (7.0% at September 30, 2002) through June 2004.           1,750                 0

  Bank Term Loan payable in monthly  installments  of $11,667 plus interest at
    1.25% above the prime rate (6.0% at September 30, 2002) through June 2007.             665                 0

  Subordinated Note - Face amount of $4,000,000, less unamortized original issue
    discount of $1,175,000 (see Note H), due June 26, 2007 plus
    interest payable monthly at 14%.                                                     2,825                 0

  Unsecured Note Payable plus interest at 3%, payable in monthly  installments
    of $2,394 through September 2006.                                                      109               122

  Unsecured Note Payable under settlement agreement with State of Florida
    Department of Revenue, payable in monthly installments of $3,500 through
    April 2006.                                                                            148               171

   Other Notes and Agreements                                                               24                38
                                                                                    -------------    --------------
  Total Long -Term Debt                                                                  8,561            11,780
  Less Current Portion                                                                  (1,169)             (968)
                                                                                    -------------    --------------
  LONG-TERM DEBT DUE AFTER 1 YEAR                                                    $   7,392       $    10,812
                                                                                    =============    ==============
</TABLE>


     In June 2002,  the Company repaid the entire  amount,  $11,310,000,  of its
bank term loan with the proceeds of a new revolving line of credit,  term loans,
a  subordinated  note and  convertible  preferred  stock.  The revolving line of
credit allows for  borrowing of up to  $5,000,000  based upon advance rates that
are  applied  to the  Company's  eligible  accounts  receivable  and  inventory.
Interest is payable on the revolving line of credit monthly based on the average
unpaid balance at the prime rate plus 1.0%.

     One term loan in the  amount of  $700,000  is  repayable  in equal  monthly
installments  over a five (5) year term,  plus  interest  at the prime rate plus
1.25%.  Another  term loan in the amount of  $2,000,000  is  repayable  in equal
monthly  installments  over two (2) years plus  interest  at the prime rate plus
2.25% and is subject to an excess cash flow payment provision.


<PAGE>
                                       9


     The subordinated  note in the amount of $4,000,000 is repayable in five (5)
years with  interest  only,  at 14%,  payable  monthly until the maturity of the
note. The subordinated  note is secured by a second lien on all of the assets of
the Company.  In addition,  the  subordinated  note holders were issued  566,517
warrants to purchase  common  stock  exercisable  for ten (10) years at $.01 per
share. (Subject to certain antidilution  provisions.) (See note H.) The relative
value of the  warrants,  and certain  imbedded  features of the  warrants,  were
recorded as part of the stockholders'  equity and reduced the carrying amount of
the subordinated note as an original issue discount. The original issue discount
is  being  amortized  over the five  (5)  year  term of the  subordinated  note.
Amortization  expense related to the original issue discount was $65,000 for the
six months ended September 30, 2002.

     The revolving  line of credit and bank term loans are  collateralized  by a
first security interest in all of the assets of the Company.

     The bank term loans also  contain  provisions  that  require the Company to
make  additional  principal  payments  based upon its excess  cash flow and also
requires  the Company to maintain  certain  financial  ratios and  stockholders'
equity  levels.  In  addition,  certain  provisions  limit the amount of capital
expenditures that the company can make each year.


NOTE G - CONTINGENCIES

     In November 1998, MTL, a discontinued operation,  received a refund request
in the amount of $1.8 million from  Medicare  Program  Safeguards  ("MPS").  MTL
disputed the refund  request in its response to MPS in December  1998.  To date,
MTL has not received any further correspondence from MPS regarding this matter.

     The Company sold the assets of subsidiaries  LifeServ and MTL during fiscal
2000. The buyers assumed certain  liabilities of these subsidiaries  including a
certain long-term obligation totaling  approximately  $120,000,  as of September
30,  2002,  payable to a financial  institution  and secured by  equipment  at a
customer  site and a contract  receivable.  The Company  was a guarantor  of the
obligation at the time the  obligation  originated and continues as a guarantor.
In  November  2002,  the  Company  received a  notification  from the  financial
institution  that the  obligation  was in default.  In addition,  the  financial
institution  advised the Company that it will seek  repayment of the  obligation
from the  Company  under  the  terms of the  guaranty.  At the time the  Company
provided its guaranty, it received an indemnification from the majority owner of
the buyer for any amounts  that it may have to pay under terms of the  guaranty.
In the event that the Company is required to repay the obligation, it intends to
seek  reimbursement  from  the  owner  of  the  buyer  under  the  terms  of the
indemnification.

     Certain creditors of LifeServ have commenced legal actions against LifeServ
seeking  payment of liabilities  assumed by the buyers of LifeServ.  The Company
intends to vigorously  defend these actions and seek  appropriate  remedies from
the buyers.

     The Company is involved in certain claims and legal actions  arising in the
ordinary course of business  including the matters referred to above.  There can
be no assurances that these matters will be resolved on terms  acceptable to the
Company.  In the  opinion  of  management,  based  upon  advice of  counsel  and
consideration  of all facts available at this time, the ultimate  disposition of
these  matters  are  not  expected  to have a  material  adverse  effect  on the
financial position, results of operations or liquidity of the Company.


<PAGE>
                                       10

NOTE H - STOCKHOLDER EQUITY

     In June 2002,  the Company  issued  subordinated  notes to an investor (see
Note F). As part of the  consideration  for the  notes,  the  investor  received
566,517 warrants to purchase common stock  exercisable at $.01 per share for ten
(10) years.

     Also in June 2002, the Company issued 2,000 shares of convertible preferred
stock at $1,000 per share.  The holders of the  convertible  preferred stock are
entitled  to  receive  quarterly  dividends  at the rate of 11% per  annum.  The
dividends are payable in cash or shares of  convertible  preferred  stock at the
Company's  option and are  cumulative.  Through the period ended  September  30,
2002,  all  dividends  due in the amount of  approximately  $58,000 were paid in
cash. The preferred  stock is  convertible  into 847,457 shares of the Company's
common  stock at $2.36 per share.  The terms of the  preferred  stock  contain a
make-whole  provision that  obligates the Company to pay certain  amounts to the
holders if they do not ultimately receive an amount equal to the price per share
of the common stock on the date they elect to convert the  preferred  stock into
common stock. On the date the convertible  preferred stock was issued,  the fair
market  value of the  Company's  common stock was $2.77 per share based upon the
closing bid on the OTC Bulletin  Board.  The difference  between the fair market
value of the shares and the conversion price of the convertible  preferred stock
represented a constructive dividend to the holders of the preferred stock in the
amount of $347,000 (See Note C).

     The terms of the warrant and convertible preferred stock agreements contain
certain  antidilution   provisions.   The  warrant  agreement  also  contains  a
make-whole  provision that  obligates the Company to pay certain  amounts to the
holders  of  the  warrants  and  convertible  preferred  stock  if  they  do not
ultimately receive an amount equal to the price per share of the common stock on
the date they  exercise  their right to purchase the common shares that underlie
the warrants.  The warrant agreement also contains a provision that may obligate
the Company to pay certain  amounts to the holders of the  warrants in the event
there is a change in control of the voting common stock of the Company, if there
is a sale of the  Company,  or if there is a public  offering  of the  Company's
common stock.

     The make-whole provision and certain antidilution provisions also represent
a contingent  beneficial  conversion feature of the convertible preferred stock.
The effect of this  feature may result in the issuance of  additional  shares at
some future date;  however,  since the issuance of these shares is contingent on
future  events,  the effect of this  feature  will be  recorded  at the time the
events occur.

     In the event the Company is required to make payments to the holders of the
warrants  and/or  preferred  stock,  it may elect to issue  additional  warrants
and/or  preferred  stock  in lieu  of  cash  payment.  Although  the  make-whole
provision  and  other  provisions  of  the  warrant  agreement  and  convertible
preferred stock agreement provide for a maximum of 12,500,000 shares that may be
issued pursuant to those provisions,  based upon current conditions, the Company
believes it is unlikely that the maximum number of shares would be issued.

     The Company has determined the value of the warrants and the make-whole and
other  provisions of the warrants and has recorded this amount as a component of
its stockholders'  equity. This amount,  $1,240,000 also represents the original
issue   discount  that  will  be  amortized  over  the  five-year  term  of  the
subordinated note.

     The Company also issued,  to its financial  advisors,  125,000  warrants to
purchase  common  stock  as part of the fees  related  to the  above  referenced
financing.  The warrants are fully  exercisable  for five (5) years at $1.50 per
share.  The value of these  warrants,  $324,000,  was determined  based upon the
value of the Company's  common stock on the date the warrants  were issued.  The
Company recorded the value of the warrants as a component of its financing costs
incurred (see Note I).


<PAGE>
                                       11



NOTE I - FINANCING COSTS

     The Company incurred  approximately  $1,458,000 during the six months ended
September 30, 2002,  including the value of the warrants issued to the Company's
financial  advisors related to obtaining certain financing  described in Notes F
and H.  The  financing  costs  were  allocated  between  the  components  of the
financing  that  represented  debt and  equity.  The  financing  costs that were
allocated to the debt proceeds, $1,090,000, have been recorded as an other asset
and will be amortized  over the  repayment  term of the various loans and notes.
The financing costs that were allocated to the equity proceeds,  $368,000,  have
been  recorded  as a  reduction  of the equity  proceeds.  Amortization  expense
related to the  financing  costs was $89,000 for the six months ended  September
30, 2002.


NOTE J - NEW ACCOUNTING PRONOUNCEMENTS

     On July 20, 2001, the Financial  Accounting  Standards  Board (FASB) issued
Statement of Financial Accounting  Standards (SFAS) 141, Business  Combinations,
and SFAS 142,  Goodwill and  Intangible  Assets.  SFAS 141 is effective  for all
business  combinations  completed after June 30, 2002. SFAS 142 is effective for
the fiscal year beginning  April 1, 2002;  however,  certain  provisions of that
Statement apply to goodwill and other intangible assets acquired between July 1,
2001 and the effective date of SFAS 142.

     In August 2001, the FASB issued SFAS No. 144, Accounting for the Impairment
or Disposal of Long-Lived Assets. This statement addresses financial  accounting
and reporting for the impairment or disposal of long-lived assets and supersedes
FASB Statement No. 121,  Accounting for the Impairment of Long-Lived  Assets and
for  Long-Lived  Assets to be Disposed Of. The  provisions  of the statement are
effective  for  financial  statements  issued for fiscal years  beginning  after
December 15, 2001.

     The  Company's  initial  analysis  of the  effect  of these  new  standards
indicates that the adoption of the standards will not have a material  impact on
its financial statements.  As of March 31, 2001 and 2002 and September 30, 2002,
no amounts of goodwill are recorded.


NOTE K - RECLASSIFICATIONS

     Certain  reclassifications  were made to the September  30, 2001  financial
statements to conform to the 2002 presentations.




<PAGE>
                                       12



NOTE L - OTHER ASSETS

     Other assets consist of the following:

<TABLE>
<CAPTION>
                                                                 September 30,               March 31,
                                                                      2002                     2002
                                                               ----------------         -----------------
                                                                            (In Thousands)
          <S>                                                  <C>                      <C>
          Product Development                                  $      1,842             $       2,202
              Less Accumulated Amortization                            (417)                     (315)
                                                               ----------------         -----------------
                                                                      1,425                     1,887
                                                               ----------------         -----------------

          Patents                                                     1,228                     1,196
              Less Accumulated Amortization                            (767)                     (725)
                                                               ----------------         -----------------
                                                                        461                       471
                                                               ----------------         -----------------

          Financing Costs                                             1,090                         0
              Less Accumulated Amortization                             (89)                        0
                                                               ----------------         -----------------
                                                                      1,001                         0
                                                               ----------------         -----------------

          Other                                                         202                       190
              Less Accumulated Amortization                             (95)                      (71)
                                                               ----------------         -----------------
                                                                        107                       119
                                                               ----------------         -----------------

          Total Other Assets Net                               $      2,994             $       2,477
                                                               ================         =================

</TABLE>


     During the six months ended  September 30, 2002,  the Company  reclassified
approximately  $554,000  of  product  development  costs  from  other  assets to
inventory.



<PAGE>
                                       13



                MEDICAL TECHNOLOGY SYSTEMS, INC. AND SUBSIDIARIES
                     MANAGEMENT'S DISCUSSION AND ANALYSIS OF
                  FINANCIAL CONDITION AND RESULTS OF OPERATIONS
              FOR THE THREE AND SIX MONTHS ENDED SEPTEMBER 30, 2002



ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
         AND RESULTS OF OPERATIONS

     This Form 10-Q contains  forward-looking  statements  within the meaning of
that term in Section  27A of the  Securities  Act of 1933 and Section 21E of the
Securities  Exchange  Act of 1934.  Additional  written or oral  forward-looking
statements  may be made by the Company  from time to time,  in filings  with the
Securities and Exchange  Commission or otherwise.  Statements  contained  herein
that are not historical  facts are  forward-looking  statements made pursuant to
the safe harbor  provisions  described  above.  Forward-looking  statements  may
include,  but are not limited to,  projections  of  revenues,  income or losses,
capital  expenditures,  plans for future  operations,  the elimination of losses
under certain  programs,  financing  needs or plans,  compliance  with financial
covenants  in loan  agreements,  plans for sale of assets or  businesses,  plans
relating to products or services of the  Company,  assessments  of  materiality,
predictions of future events and the effects of pending and possible litigation,
as well as assumptions relating to the foregoing. In addition, when used in this
discussion,  the  words  "anticipates",   "estimates",   "expects",   "intends",
"believes",  "plans" and variations thereof and similar expressions are intended
to identify forward-looking statements.

     Forward-looking   statements   are   inherently   subject   to  risks   and
uncertainties,  some of which can be  predicted or  quantified  based on current
expectations.  Consequently,  future  events and  actual  results  could  differ
materially  from  those  set  forth  in,  contemplated  by,  or  underlying  the
forward-looking  statements  contained  herein.  Statements in Quarterly Report,
particularly  in "Item 2.  Management's  Discussion  and  Analysis of  Financial
Condition  and  Results  of  Operations"  and  Notes to  Condensed  Consolidated
Financial Statements,  describe factors,  among others, that could contribute to
or cause such differences.  Other factors that could contribute to or cause such
differences  include,  but  are  not  limited  to,  unanticipated  increases  in
operating costs, labor disputes,  capital  requirements,  increases in borrowing
costs, product demand, pricing, market acceptance,  intellectual property rights
and  litigation,  risks in product  and  technology  development  and other risk
factors detailed in the Company's Securities and Exchange Commission filings. In
particular  any  comments  regarding  possible  default  waivers  related to the
Company's loan agreement are forward-looking statements.

     Readers are  cautioned not to place undue  reliance on any  forward-looking
statements contained herein, which speak only as of the date hereof. The Company
undertakes  no  obligation  to publicly  release the result of any  revisions of
these  forward-looking  statements  that  may  be  made  to  reflect  events  or
circumstances  after the date hereof or to reflect the  occurrence of unexpected
events.


RESULTS OF OPERATIONS

Three Months Ended September 30, 2002 and 2001
----------------------------------------------

     Net sales for the three months ended  September 30, 2002 increased 11.7% to
$6.7 million from $6.0 million  during the same period the prior year. Net sales
increased primarily as a result of an increase in the amount of disposable punch
cards and machines  sold to new and existing  customers.  Prices for  disposable
products were stable  compared to the prior year. The Company  anticipates  that
pricing on  disposables  will  continue to be stable  through the balance of the
fiscal  year.  The  volume  of  disposable   cards  and  machines  is  currently
anticipated  to continue to grow as a result of the addition of new customers in
existing and new markets.

     Cost of sales for the three months ended September 30, 2002 increased 17.1%
to $4.1 million from $3.5 million during the same period the prior year. Cost of
sales as a  percentage  of sales  increased  to 61.2% from 58.3% during the same
period the prior year.  The  increase in cost of sales  primarily  results  from
increased  costs  associated  with  higher  revenue.  The  higher  costs,  as  a
percentage of sales,  result primarily from the addition of personnel in factory
operations in anticipation of expected growth in revenue,  as well as the launch
of the OnDemand machine.



<PAGE>
                                       14



     Selling,  general and  administration  expenses  for the three months ended
September 30, 2002 increased 15.4% to $1.5 million from $1.3 million in the same
period  during  the prior  year  primarily  due to  increased  personnel  costs,
training,  marketing  expenditures  and  costs  associated  with  the  Company's
operations in the United Kingdom.

     Depreciation and amortization expenses for the three months ended September
30, 2002  increased  7.7% to $251,000 from  $233,000  during the same period the
prior year. The increase results  primarily from the fact that the Company began
to amortize  the  capitalized  development  costs  associated  with the OnDemand
product during the three months ended September 30, 2002.

     Other  expenses  related  to the June  2002  refinancing  of the  Company's
long-term debt were $147,000  during the three months ended  September 30, 2002.
These expenses  resulted from the  amortization of certain costs associated with
the  financing  ($85,000)  as well as the  amortization  of the  original  issue
discount  associated  with  the  subordinated  debt  portion  of the  financing,
($62,000).

     Interest  expense for the three months ended  September 30, 2002  decreased
5.4% to  $228,000  from  $241,000  during the same  period the prior  year.  The
decrease  results from a reduction in  outstanding  debt that  resulted from the
June 2002 refinancing.

     Income tax  expense  decreased  25.3% to $177,000  during the three  months
ended  September  30, 2002  compared to $237,000  the prior year.  The  decrease
results from lower income tax expense associated with lower income.


Six Months Ended September 30, 2002 and 2001
--------------------------------------------

     Net sales for the six months ended  September 30, 2002  increased  14.3% to
$13.6  million  from $11.9  million  during the same period the prior year.  Net
sales increased primarily as a result of an increase in the amount of disposable
punch  cards  and  machines  sold  to new and  existing  customers.  Prices  for
disposable products were stable compared to the prior year. In addition, one (1)
OnDemand  machine was sold during the six months ended  September 30, 2002.  The
Company  anticipates  that  pricing on  disposables  will  continue to be stable
through  the  balance of the fiscal  year.  The volume of  disposable  cards and
machines  is  currently  anticipated  to  continue  to grow as a  result  of the
addition of new customers in existing and new markets.

     Cost of sales for the six months ended  September 30, 2002 increased  20.0%
to $8.4 million from $7.0 million during the same period the prior year. Cost of
sales as a  percentage  of sales  increased  to 61.8% from 58.8% during the same
period the prior year.  The  increase in cost of sales  primarily  results  from
increased  costs  associated  with higher  revenue.  The increase in the cost of
sales as a percentage  of sales results  primarily  from higher  overhead  costs
incurred  compared  to the same  period the prior  year.  The  higher  costs are
related  primarily  to the  addition  of  personnel  in  factory  operations  in
anticipation  of  expected  growth  in  revenue,  as well as the  launch  of the
OnDemand machine.

     Selling,  general  and  administration  expenses  for the six months  ended
September 30, 2002 increased 11.1% to $3.0 million from $2.7 million in the same
period  during  the prior  year  primarily  due to  increased  personnel  costs,
training,  marketing  expenditures  and  costs  associated  with  the  Company's
operations in the United Kingdom.

     Depreciation and  amortization  expenses for the six months ended September
30, 2002  decreased  4.5% to $436,000 from  $457,000  during the same period the
prior year.  The decrease  results  primarily  from the fact that certain assets
became fully depreciated since September 30, 2001.



<PAGE>
                                       15


     Other  expenses  related  to the June  2002  refinancing  of the  Company's
long-term  debt were  $154,000  during the six months ended  September 30, 2002.
These expenses  resulted from the  amortization of certain costs associated with
the  financing  ($89,000)  as well as the  amortization  of the  original  issue
discount  associated  with  the  subordinated  debt  portion  of  the  financing
($65,000).

     Interest expense for the six months ended September 30, 2002 decreased 6.6%
to $449,000  from $481,000  during the same period the prior year.  The decrease
results from a reduction in  outstanding  debt  resulting  from regular  monthly
principal  payments made according to the terms of the Company's loan agreements
as well as a reduction  in  outstanding  debt that  resulted  from the June 2002
refinancing.

     Income tax expense  decreased 8.0% to $438,000  during the six months ended
September  30, 2002  compared to $476,000 the prior year.  The decrease  results
from lower income tax expense associated with lower income.


LIQUIDITY AND CAPITAL RESOURCES

     During the six months ended  September 30, 2002, the Company had net income
of $725,000  compared to net income of $822,000 the prior year. Cash provided by
operating  activities was $1,846,000  during the six months ended  September 30,
2002 compared to $1,714,000  provided in the prior year. The Company had working
capital of $3,344,000 at September 30, 2002.

     The increase in cash provided by operating activities during the six months
ended  September  30,  2002  compared  to the same  period  the  prior  year was
primarily  due to  faster  collection  of  accounts  receivable  resulting  from
increased collection efforts.

     Investing  activities  used $806,000  during the six months ended September
30, 2002  compared to $973,000 the prior year.  The decrease  results  primarily
from a reduction in expenditures  for  improvements to the Company's  facilities
and lower expenditures for capitalized development costs related to the OnDemand
machine.

     Financing  activities used $1,230,000 during the six months ended September
30, 2002 compared to $743,000 the prior year.  The increase  resulted  primarily
from the costs associated with the refinance of the Company's long-term debt. In
June 2002, the Company repaid the entire amount,  $11,310,000,  of its bank term
loan with cash on hand,  the proceeds of a new  revolving  line of credit,  term
loans, a subordinated  note and convertible  preferred stock. The revolving line
of credit allows for borrowing of up to $5,000,000 based upon advance rates that
are  applied  to the  Company's  eligible  accounts  receivable  and  inventory.
Interest is payable on the revolving line of credit monthly based on the average
unpaid balance at the prime rate plus 1.0%.

     One term loan in the  amount of  $700,000  is  repayable  in equal  monthly
installments  over a five (5) year term,  plus  interest  at the prime rate plus
1.25%.  Another  term loan in the amount of  $2,000,000  is  repayable  in equal
monthly  installments  over two (2) years plus  interest  at the prime rate plus
2.25% and is subject to an excess cash flow payment provision.

     The  revolving  line of  credit  and the  term  loans  are  secured  by the
Company's accounts receivable,  inventory, machinery and equipment and all other
assets of the Company.

     The subordinated  note in the amount of $4,000,000 is repayable in five (5)
years with  interest  only,  at 14%,  payable  monthly until the maturity of the
note. The subordinated  note is secured by a second lien on all of the assets of
the Company.  In addition,  the  subordinated  note holders were issued  566,517
warrants to purchase  common  stock  exercisable  for ten (10) years at $.01 per
share. (Subject to certain antidilution provisions.)


<PAGE>
                                       16


     The Company  issued 2,000 shares of convertible  preferred  stock at $1,000
per share.  The  holders of the  convertible  preferred  stock are  entitled  to
receive  quarterly  dividends at the rate of 11% per annum.  The  dividends  are
payable  in cash or shares of  convertible  preferred  stock,  at the  Company's
option,  and are  cumulative.  The preferred  stock is convertible  into 847,457
shares of the  Company's  common  stock at $2.36 per share.  (Subject to certain
antidilution provisions.)

     The warrant  agreement  and the terms of the  convertible  preferred  stock
contain a make-whole provision that obligates the Company to pay certain amounts
to the holders of the warrants and  convertible  preferred  stock if they do not
ultimately receive an amount equal to the price per share of the common stock on
the date they  exercise  their right to purchase the common shares that underlie
the warrants and the convertible  preferred  stock.  The warrant  agreement also
contains a provision that may obligate the Company to pay certain amounts to the
holders  of the  warrants  in the event that there is a change in control of the
voting  common  stock of the Company,  if there is a sale of the Company,  or if
there is a public offering of the Company's common stock.

     In the event that the Company is  required to make  payments to the holders
of the  warrants  and/or  preferred  stock,  it may  elect to  issue  additional
warrants  and/or  preferred  stock  in  lieu  of a cash  payment.  Although  the
make-whole   provision  and  other  provisions  of  the  warrant  agreement  and
convertible preferred stock agreement provide for a maximum of 12,500,000 shares
that may be issued pursuant to those provisions,  based upon current conditions,
the Company  believes it is unlikely that the maximum  number of shares would be
issued.

     The revolving  line of credit,  the term loans and the  subordinated  notes
each contain certain financial covenants that, among other things,  requires the
maintenance  of  certain  financial   ratios,   limits  the  amount  of  capital
expenditures and requires the Company to obtain the lenders approval for certain
matters.

     The Company's  short-term and long-term liquidity is primarily dependent on
its ability to generate cash flow from  operations.  Inventory levels may change
significantly  if the Company is  successful  in selling its  OnDemand  machine.
Increases  in net  sales may  result  in  corresponding  increases  in  accounts
receivable.  Cash  flow  from  operations  and  borrowing  availability  on  the
revolving  line of credit is  anticipated  to support an  increase  in  accounts
receivable and inventory.

     The Company has several new product development  projects underway that are
expected to be funded by cash flow from operations. These projects are monitored
on a regular basis to attempt to ensure that the  anticipated  costs  associated
with them do not exceed the  Company's  ability to fund them from cash flow from
operations.

     The Company  believes that the cash generated from  operations  during this
fiscal  year is  expected to be  sufficient  to meet its  capital  expenditures,
product  development,  working capital needs and the principal payments required
by its loan agreements.



<PAGE>
                                       17


ITEM 3.  QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

     While we had no holdings of derivative  financial or commodity  investments
at September  30,  2002,  we are exposed to financial  market  risks,  including
changes in  interest  rates.  Although  certain of our  borrowings  bear a fixed
interest  rate,  our  borrowings  under our revolving line of credit and certain
term loans bear interest at a variable rate based upon the prime rate.


ITEM 4.  CONTROLS AND PROCEDURES

     A. Evaluation of Disclosure Controls and Procedures

          Disclosure  controls  and  procedures  are  designed  to  ensure  that
          information required to be disclosed in the reports filed or submitted
          under  the  Exchange  Act  is  recorded,  processed,   summarized  and
          reported,  within the time  periods  specified  in the SEC's rules and
          forms. Disclosure controls and procedures include, without limitation,
          controls and procedures  designed to ensure that information  required
          to be  disclosed  in the  reports  filed  under  the  Exchange  Act is
          accumulated  and  communicated  to  management,  including  the  Chief
          Executive  Officer and Chief Financial  Officer,  as  appropriate,  to
          allow timely decisions  regarding required  disclosure.  Within the 90
          days prior to the filing of this  report,  the Company  carried out an
          evaluation,  under the supervision and with the  participation  of the
          Company's management,  including the Company's Chief Executive Officer
          and Chief Financial  Officer,  of the  effectiveness of the design and
          operation of the  Company's  disclosure  controls and  procedures  (as
          defined in Exchange Act Rules 15a-14(c) and 15d-14(c)). Based upon and
          as of the date of that evaluation,  Chief Executive  Officer and Chief
          Financial Officer concluded that the Company's disclosure controls and
          procedures  are  effective to ensure that  information  required to be
          disclosed  in the  reports the  Company  files and  submits  under the
          Exchange Act is  recorded,  processed  summarized  and reported as and
          when required.

     B. Changes in Internal Controls

          There were no significant  changes in the Company's  internal controls
          or other  factors  that  could  significantly  affect  those  controls
          subsequent  to  the  date  of the  Company's  most  recent  evaluation
          including   any   corrective   actions  with  regard  to   significant
          deficiencies and material weaknesses.




<PAGE>
                                       18


PART II - OTHER INFORMATION
---------------------------


Item 4.  Submission of Matters to a Vote of Security-Holders.

     The Annual Meeting of the Shareholders of the Company was held on September
24, 2002. Messrs. Todd E. Siegel,  David Kazarian,  Michael Conroy, John Stanton
and Frank Newman were elected directors of the Company for one-year terms. There
were a total of 5,056,709 shares of Common Stock voted. Each nominee received at
least 5,017,063 votes.

     Grant  Thornton LLP was  ratified as the  Company's  independent  certified
public  accountants  for fiscal year 2003 with 5,056,207  shares of Common Stock
voted in favor,  360 shares of Common  Stock  voted  against,  and 142 shares of
Common Stock abstained.


Item 6.  Exhibits and Reports on Form 8-K


     A.    Reports on Form 8K

           None

     B.    Exhibit 99.1

           Certification Pursuant to 18 U.S.C.ss.1350

     C.    Exhibit 99.2

           Certification Pursuant to 18 U.S.C.ss.1350


Signatures
----------

     Pursuant to the  requirements  of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned thereunto duly authorized.


                        MEDICAL TECHNOLOGY SYSTEMS, INC.


Date:  November 14, 2002            By:     /s/ Michael P. Conroy
-------------------------           ----------------------------------------
                                    Michael P. Conroy
                                    Vice President & Chief Financial Officer



Date:  November 14, 2002            By:     /s/ Mark J. Connolly
-------------------------           ----------------------------------------
                                    Mark J. Connolly
                                    Principal Accounting Officer and Controller


<PAGE>
                                       19


                                 CERTIFICATIONS


I, Todd E. Siegel, certify that:

1.   I have reviewed this  quarterly  report on Form 10-Q of Medical  Technology
     Systems, Inc.;

2.   Based on my knowledge,  this  quarterly  report does not contain any untrue
     statement of a material fact or omit to state a material fact  necessary to
     make the statements  made, in light of the  circumstances  under which such
     statements  were made, not misleading with respect to the period covered by
     this quarterly report;

3.   Based on my  knowledge,  the  financial  statements,  and  other  financial
     information  included  in this  quarterly  report,  fairly  present  in all
     material respects the financial  condition,  results of operations and cash
     flows of the  registrant  as of, and for,  the  periods  presented  in this
     quarterly report;

4.   The  registrant's  other  certifying  officers  and I are  responsible  for
     establishing and maintaining disclosure controls and procedures (as defined
     in Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:

     a)   designed  such  disclosure  controls  and  procedures  to ensure  that
          material  information  relating  to  the  registrant,   including  its
          consolidated subsidiaries,  is made known to us by others within those
          entities,  particularly  during  the  period in which  this  quarterly
          report is being prepared;

     b)   evaluated the  effectiveness of the registrant's  disclosure  controls
          and procedures as of a date within 90 days prior to the filing date of
          this quarterly report (the "Evaluation Date"); and

     c)   presented  in  this  quarterly   report  our  conclusions   about  the
          effectiveness  of the disclosure  controls and procedures based on our
          evaluation as of the Evaluation Date;

5.   The registrant's other certifying  officers and I have disclosed,  based on
     our most recent  evaluation,  to the  registrant's  auditors  and the audit
     committee of  registrant's  board of directors (or persons  performing  the
     equivalent function):

     a)   all  significant  deficiencies  in the design or operation of internal
          controls  which could  adversely  affect the  registrant's  ability to
          record,  process,   summarize  and  report  financial  data  and  have
          identified for the  registrant's  auditors any material  weaknesses in
          internal controls; and

     b)   any fraud, whether or not material,  that involves management or other
          employees who have a  significant  role in the  registrant's  internal
          controls; and

6.   The  registrant's  other  certifying  officers and I have indicated in this
     quarterly report whether or not there were significant  changes in internal
     controls  or in other  factors  that could  significantly  affect  internal
     controls  subsequent to the date of our most recent  evaluation,  including
     any corrective actions with regard to significant deficiencies and material
     weaknesses.


     Date:  November 14, 2002               By: /s/ Todd E. Siegel
     -------------------------              ----------------------------------
                                            Todd E. Siegel
                                            President & Chief Executive Officer


<PAGE>
                                       20



I, Michael P. Conroy, certify that:

1.   I have reviewed this  quarterly  report on Form 10-Q of Medical  Technology
     Systems, Inc.;

2.   Based on my knowledge,  this  quarterly  report does not contain any untrue
     statement of a material fact or omit to state a material fact  necessary to
     make the statements  made, in light of the  circumstances  under which such
     statements  were made, not misleading with respect to the period covered by
     this quarterly report;

3.   Based on my  knowledge,  the  financial  statements,  and  other  financial
     information  included  in this  quarterly  report,  fairly  present  in all
     material respects the financial  condition,  results of operations and cash
     flows of the  registrant  as of, and for,  the  periods  presented  in this
     quarterly report;

4.   The  registrant's  other  certifying  officers  and I are  responsible  for
     establishing and maintaining disclosure controls and procedures (as defined
     in Exchange Act Rules 13a-14 and 15d-14) for the registrant and we have:

     a)   designed  such  disclosure  controls  and  procedures  to ensure  that
          material  information  relating  to  the  registrant,   including  its
          consolidated subsidiaries,  is made known to us by others within those
          entities,  particularly  during  the  period in which  this  quarterly
          report is being prepared;

     b)   evaluated the  effectiveness of the registrant's  disclosure  controls
          and procedures as of a date within 90 days prior to the filing date of
          this quarterly report (the "Evaluation Date"); and

     c)   presented  in  this  quarterly   report  our  conclusions   about  the
          effectiveness  of the disclosure  controls and procedures based on our
          evaluation as of the Evaluation Date;

5.   The registrant's other certifying  officers and I have disclosed,  based on
     our most recent  evaluation,  to the  registrant's  auditors  and the audit
     committee of  registrant's  board of directors (or persons  performing  the
     equivalent function):

     a)   all  significant  deficiencies  in the design or operation of internal
          controls  which could  adversely  affect the  registrant's  ability to
          record,  process,   summarize  and  report  financial  data  and  have
          identified for the  registrant's  auditors any material  weaknesses in
          internal controls; and

     b)   any fraud, whether or not material,  that involves management or other
          employees who have a  significant  role in the  registrant's  internal
          controls; and

6.   The  registrant's  other  certifying  officers and I have indicated in this
     quarterly report whether or not there were significant  changes in internal
     controls  or in other  factors  that could  significantly  affect  internal
     controls  subsequent to the date of our most recent  evaluation,  including
     any corrective actions with regard to significant deficiencies and material
     weaknesses.


     Date:  November 14, 2002          By:  /s/ Michael P. Conroy
    -------------------------          ---------------------------------------
                                       Michael P. Conroy
                                       Vice President & Chief Financial Officer



<PAGE>
                                       21


Exhibit 99.1


CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Medical Technology Systems, Inc. (the
"Company")  on Form 10-Q for the period ended  September  30, 2002 as filed with
the Securities and Exchange  Commission on the date hereof (the "Form 10-Q"), I,
Todd E. Siegel,  President and Chief Executive Officer of the Company,  certify,
pursuant  to  18  U.S.C.   ss.1350,   as  adopted  pursuant  to  ss.906  of  the
Sarbanes-Oxley Act of 2002, that:

(1)  The Form 10-Q fully  complies  with the  requirements  of Section  13(a) or
     15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and

(2)  The information contained in the Form 10-Q fairly presents, in all material
     respects, the financial condition and results of operations of the Company.


Dated:  November 14, 2002

/s/ Todd E. Siegel
--------------------------------------
Todd E. Siegel
President and Chief Executive Officer





<PAGE>
                                       22


Exhibit 99.2


CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Medical Technology Systems, Inc. (the
"Company")  on Form 10-Q for the period ended  September  30, 2002 as filed with
the Securities and Exchange  Commission on the date hereof (the "Form 10-Q"), I,
Michael P. Conroy,  Vice President and Chief  Financial  Officer of the Company,
certify,  pursuant to 18 U.S.C.  ss.1350,  as adopted  pursuant to ss.906 of the
Sarbanes-Oxley Act of 2002, that:

(1)  The Form 10-Q fully  complies  with the  requirements  of Section  13(a) or
     15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and

(2)  The information contained in the Form 10-Q fairly presents, in all material
     respects, the financial condition and results of operations of the Company.

Dated:  November 14, 2002



/s/ Michael P. Conroy
----------------------------------------
Michael P. Conroy
Vice President & Chief Financial Officer